Abstract
Despite efforts, brain metastases (BM) remain a critical issue in the management of patients affected by non-small-cell lung cancer (NSCLC). To date, radiotherapy is still considered the gold standard treatment; on the other hand, systemic chemotherapeutical agents are not so often an effective therapy for BM, whereas targeted agents in oncogene-addicted disease have shown a good activity also on BM. Anti-programmed death-1/programmed death ligand-1 agents represent a new valid therapeutic strategy for NSCLC as well as for several tumor types, but their efficacy on patients with BM is still unclear mainly due to the strict selection criteria adopted in clinical trials. The aim of the present article is to discuss the potential activity of checkpoint inhibitors in patients with BM from NSCLC.
| Original language | English |
|---|---|
| Pages (from-to) | 403-410 |
| Number of pages | 8 |
| Journal | Immunotherapy |
| Volume | 10 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - Apr 1 2018 |
Fingerprint
Keywords
- brain metastases NSCLC
- checkpoint inhibitors blood-brain barrier
- immunotherapy blood-brain barrier
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Oncology
Cite this
Checkpoint inhibitors : 'Raising the bar' also in brain metastases from non-small-cell lung cancer? / Rossi, Sabrina; Finocchiaro, Giovanna; Marchetti, Silvia; Toschi, Luca; Santoro, Armando.
In: Immunotherapy, Vol. 10, No. 5, 01.04.2018, p. 403-410.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Checkpoint inhibitors
T2 - 'Raising the bar' also in brain metastases from non-small-cell lung cancer?
AU - Rossi, Sabrina
AU - Finocchiaro, Giovanna
AU - Marchetti, Silvia
AU - Toschi, Luca
AU - Santoro, Armando
PY - 2018/4/1
Y1 - 2018/4/1
N2 - Despite efforts, brain metastases (BM) remain a critical issue in the management of patients affected by non-small-cell lung cancer (NSCLC). To date, radiotherapy is still considered the gold standard treatment; on the other hand, systemic chemotherapeutical agents are not so often an effective therapy for BM, whereas targeted agents in oncogene-addicted disease have shown a good activity also on BM. Anti-programmed death-1/programmed death ligand-1 agents represent a new valid therapeutic strategy for NSCLC as well as for several tumor types, but their efficacy on patients with BM is still unclear mainly due to the strict selection criteria adopted in clinical trials. The aim of the present article is to discuss the potential activity of checkpoint inhibitors in patients with BM from NSCLC.
AB - Despite efforts, brain metastases (BM) remain a critical issue in the management of patients affected by non-small-cell lung cancer (NSCLC). To date, radiotherapy is still considered the gold standard treatment; on the other hand, systemic chemotherapeutical agents are not so often an effective therapy for BM, whereas targeted agents in oncogene-addicted disease have shown a good activity also on BM. Anti-programmed death-1/programmed death ligand-1 agents represent a new valid therapeutic strategy for NSCLC as well as for several tumor types, but their efficacy on patients with BM is still unclear mainly due to the strict selection criteria adopted in clinical trials. The aim of the present article is to discuss the potential activity of checkpoint inhibitors in patients with BM from NSCLC.
KW - brain metastases NSCLC
KW - checkpoint inhibitors blood-brain barrier
KW - immunotherapy blood-brain barrier
UR - http://www.scopus.com/inward/record.url?scp=85042671914&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042671914&partnerID=8YFLogxK
U2 - 10.2217/imt-2017-0151
DO - 10.2217/imt-2017-0151
M3 - Review article
C2 - 29473467
AN - SCOPUS:85042671914
VL - 10
SP - 403
EP - 410
JO - Immunotherapy
JF - Immunotherapy
SN - 1750-743X
IS - 5
ER -